Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1473-3099(17)30367-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.
J Infect Dis
January 2019
Infection, Immunity, and Inflammation Programme.
Objective: Immune activation is associated with morbidity and mortality during human immunodeficiency virus (HIV) infection, despite receipt of antiretroviral therapy (ART). We investigated whether microbial translocation drives immune activation in HIV-infected Ugandan children.
Methods: Nineteen markers of immune activation and inflammation were measured over 96 weeks in HIV-infected Ugandan children in the CHAPAS-3 Trial and HIV-uninfected age-matched controls.
Multidisciplinary and multisectoral coalitions as catalysts for action against antimicrobial resistance: Implementation experiences at national and regional levels.
Glob Public Health
December 2018
i Food, Medicine and Health Care Administration and Control Authority , Addis Ababa , Ethiopia.
The multi-faceted complexities of antimicrobial resistance (AMR) require consistent action, a multidisciplinary approach, and long-term political commitment. Building coalitions can amplify stakeholder efforts to carry out effective AMR prevention and control strategies. We have developed and implemented an approach to help local stakeholders kick-start the coalition-building process.
View Article and Find Full Text PDFAbacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Lancet Infect Dis
February 2016
Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address:
Background: WHO 2013 guidelines recommend universal treatment for HIV-infected children younger than 5 years. No paediatric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in first-line antiretroviral therapy (ART) in Africa, where most HIV-infected children live. We aimed to compare stavudine, zidovudine, or abacavir as dual or triple fixed-dose-combination paediatric tablets with lamivudine and nevirapine or efavirenz.
View Article and Find Full Text PDFEvaluation of a density-based rapid diagnostic test for sickle cell disease in a clinical setting in Zambia.
PLoS One
September 2015
Department of Chemistry & Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America; Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, Massachusetts, United States of America.
Although simple and low-cost interventions for sickle cell disease (SCD) exist in many developing countries, child mortality associated with SCD remains high, in part, because of the lack of access to diagnostic tests for SCD. A density-based test using aqueous multiphase systems (SCD-AMPS) is a candidate for a low-cost, point-of-care diagnostic for SCD. In this paper, the field evaluation of SCD-AMPS in a large (n = 505) case-control study in Zambia is described.
View Article and Find Full Text PDFBackground: Few studies have investigated objective markers of lipodystrophy in African children. We compared body circumferences, skin-fold thickness (SFT) and lipids in antiretroviral therapy (ART)-naive and stavudine (d4T)-exposed children with HIV-uninfected controls.
Methods: In the CHAPAS-3 trial, HIV-infected children (ART-naive or on d4T for ≥2 years without clinical lipodystrophy) were randomized to d4T, abacavir or zidovudine with lamivudine (3TC) plus a non-nucleoside reverse transcriptase inhibitor.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!